62 W. Fathalla et al.
4.9. 3-Cyclohexyl 1-[N-(2-chloro-5-nitro-phenyl)-benzimidoyl] thiourea (3i)
Colorless crystals (0.42 g, 45%); mp 168–169◦C. 1H NMR (300 MHz, CDCl3): δ 11.41 (1H, s,
N-H), 8.24 (1H, s, N-H), 7.48 (1H, d, J = 8.0 Hz, Ar-H), 7.47–7.16 (7H, m, Ar-H), 4.64–4.57
(1H, m, CH), 2.44–2.27 (2H, m, CH2), 1.91–1.71 (4H, m, 2CH2), 1.59–1.33 (4H, m, 2CH2). 13C-
NMR (CDCl3): δ 178.34 (C9S), 157.90 (Cq), 146.82 (Cq), 145.65 (Cq), 134.47 (Cq), 133.01 (Cq),
131.65 (CHAr), 131.49 (Cq), 130.41 (CHAr), 129.52 (CHAr), 128.95 (CHAr), 127.48 (CHAr),
119.47 (CHAr), 118.41 (CHAr), 54.73 (CH), 31.86 (CH2), 25.71 (CH2), 24.48 (CH2). Anal.
Calcd. For C20H21ClN4O2S (416.9): C, 57.62; H, 5.08; Cl, 8.50; N, 13.44; S, 7.69; Found: C,
57.45; H, 4.93; N, 13.36.
4.10. N-(2-Chloro-5-nitro-phenyl)-Nꢀ-cyclohexyl-benzamidine (10)
Yellowish crystals (0.41 g, 51%); mp 122–123◦C. H NMR (300 MHz, CDCl3): δ 7.95 (1H, d,
1
J = 8.0 Hz, Ar-H), 7.66–7.45 (3H, m, Ar-H), 7.32–7.18 (4H, m, Ar-H), 4.78–4.67 (1H, m, CH),
4.01 (1H, s, N-H), 2.34–2.08 (1H, m, CH2), 2.34–2.08 (1H, m, CH2), 2.34–2.08 (2H, m, CH2),
1.74–1.22 (8H, m, 2CH2). 13C-NMR (CDCl3): δ 158.39 (Cq), 150.23 (Cq), 146.85 (Cq), 135.95
(Cq), 134.75 (Cq), 133.94 (CHAr), 130.01 (CHAr), 129.80 (CHAr), 129.36 (CHAr), 128.82
(CHAr), 119.31 (CHAr), 116.76 (CHAr), 50.61(CH), 33.24 (CH2), 26.19 (CH2), 25.21 (CH2).
Anal. Calcd. For C19H20ClN3O2 (357.8): C, 63.77; H, 5.63; Cl, 9.91; N, 11.74; Found: C, 63.68;
H, 5.47; N, 11.51.
Acknowledgement
We would like to thank Dr Mustafa Aly Faculty of Science, Port-Said University, Egypt for technical support.
References
(1) Ahgren, C.; Backro, K.; Bell, F.W.; Cantrell, A.S.; Clemens, M.; Colacino, J. ; Deeter, M.J.B.; Engelhardt, J.A.;
Jaskunas, S.R.; Johansson, N.G.; Jordan, C.L.; Kasher, J.S.; Kinnick, M.D.; Lind, P.; Lopez, C.; Morin, J.M.;
Muesing, M.A.; Noreen, R.; Oberg, B.; Paget, C.J.; Palkowitz, J.A.; Parrish, C.; Pranc, P.; Rippy, M.K.; Rydergard,
C.; Sahlberg, C.; Swanson, S.; Ternansky, R.; Unge, J.; Vasileff, T.R.T.; Vrang, L.; West, S.J.; Zhang, H.; Zhou, X.X.
Antimicrob. Agents Chemother. 1995, 39, 1329–1335.
(2) Heinisch, G.; Matuszczak, B.; Pachler, S.; Rakowitz, D. Antivir. Chem. Chemother. 1997, 8, 443–446.
(3) Ren, J.; Diprose, J.; Warren, J.; Esnouf, R.M.; Bird, L.E.; Ikemizu, S.; Slater, M.; Milton, J.; Balzarini, J.; Stuart,
D.I; Stammers, D.K. J. Biol. Chem. 2000, 275, 5633–5639.
(4) Uckun, F.M.; Venkatachalam, T.K. United States Patent 6960606, 2005.
(5) Brown, D.J. In Comprehensive Heterocyclic Chemistry; Katritzky, A.R.; Rees, C.W., Eds.; Pergamon Press: Oxford,
1984; Vol. 3.
(6) Kappe, C.O. Tetrahedron 1993, 49, 6937–6963.
(7) Liu, H.-L.; Zongcheng Li, Z.; Anthonsen, T. Molecules 2000, 5, 1055–1061.
(8) Fathalla, W. ARKIVOC 2008, xii, 245–255.
(9) Racané, L.; Kralj, M.; Suman, L.; Stojkoviæ, R.; Traliæ-Kulenovic´, V.; Karminski-Zamola, G. Bioorg. Med. Chem.
2010, 18, 1038–1044.
(10) Bradshaw, T.D.;Wrigley, S.; Shi, D.-F.; Schultz, R.J.; Paull, K.D.; Stevens, M.F.G. Brit. J. Cancer 1998, 77, 745–752.
(11) Belluti, F.; Fontana, G.; Dal Bo, L.; Carenini, N.; Giommarelli, C.; Zunino, F.; Bioorg. Med. Chem. 2010, 18,
3543–3550.
(12) Gupta, M.; Mazumdar, U.K.; Kumar, R.S.; Shivakumar, T. Pharmacol. Sin. 2004, 25, 1070–1076.
(13) Khanam, J.A.; Bag, S.P. Ind. J. Pharm. 1997, 29, 157–161.
(14) Ben-Alloum, A.; Bakkas, S.; Soufiaoui, M. Tetrahedron Lett. 1997, 38, 6395–6396.
(15) Hutchinson, I.; Stevens, M.F.G.; Westwell, A.D. Tetrahedron Lett. 2000, 41, 425–428.
(16) Alagile, D.; Baldwin, R.M.; Tamagnan, G.D. Tetrahedron Lett. 2005, 46, 1349–1351.
(17) Serdons, K.; Terwinghe, C.; Vermaelen, P.; Van Laere, K.; Kung, H.; Mortelmans, L.; Bormans, G.; Verbruggen, A.
J. Med. Chem. 2009, 52, 1428–1437.
(18) Fathalla, W.; Cajan, M.; Marek, J.; Pazdera, P. Molecules 2001, 6, 588–602.
(19) Fathalla, W.; Pazdera, P. ARKIVOC 2002, i, 7–11.